Literature DB >> 1567466

The mechanism of bioactivation and antigen formation of amodiaquine in the rat.

A C Harrison1, N R Kitteringham, J B Clarke, B K Park.   

Abstract

A glutathione conjugate of amodiaquine has been isolated and characterized from rat bile after administration of [14C]amodiaquine (50 mumol/kg, 5.0 muCi/rat) to anaesthetized male Wistar rats. Thioether conjugates of amodiaquine in rat bile accounted for a total of 12% of the dose, 5 hr after administration of the drug. In addition, 1% of the dose remained in the liver covalently bound to tissue proteins after 5 hr. These findings provide direct evidence that a chemically reactive metabolite, amodiaquine quinoneimine, has been formed from the drug in vivo. A second major metabolite, desethylamodiaquine, accounting for 14% of the given dose, was present in the liver after 5 hr. Enzyme inhibition studies with ketoconazole-pretreated rats showed that both amodiaquine quinoneimine and desethylamodiaquine formation can be catalysed by cytochrome P450. The demonstration that amodiaquine readily and extensively forms a metabolite in vivo, with strong reactivity towards protein and non-protein thiol groups, may help to explain the idiosyncratic toxicity observed in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567466     DOI: 10.1016/0006-2952(92)90198-r

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Can pharmacogenomics improve malaria drug policy?

Authors:  Mary W Roederer; Howard McLeod; Jonathan J Juliano
Journal:  Bull World Health Organ       Date:  2011-09-01       Impact factor: 9.408

2.  Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component.

Authors:  S R Hawley; P G Bray; P M O'Neill; D J Naisbitt; B K Park; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine, or pyronaridine.

Authors:  B M Kotecka; G B Barlin; M D Edstein; K H Rieckmann
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  Science, medicine and clinical pharmacology. The Lilly Lecture 1994.

Authors:  A Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

5.  Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.

Authors:  Yongjie Zhang; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Clin Pharmacol       Date:  2016-11-16       Impact factor: 4.335

6.  Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development.

Authors:  M Pirmohamed; K Park
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

Review 7.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Effect of disposition of mannich antimalarial agents on their pharmacology and toxicology.

Authors:  J E Ruscoe; M D Tingle; P M O'Neill; S A Ward; B K Park
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

9.  Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.

Authors:  Shalenie P den Braver-Sewradj; Michiel W den Braver; Robin M Toorneman; Stephanie van Leeuwen; Yongjie Zhang; Stefan J Dekker; Nico P E Vermeulen; Jan N M Commandeur; J Chris Vos
Journal:  Chem Res Toxicol       Date:  2018-01-11       Impact factor: 3.739

10.  Glutathione S-Transferase P1 Protects Against Amodiaquine Quinoneimines-Induced Cytotoxicity but Does Not Prevent Activation of Endoplasmic Reticulum Stress in HepG2 Cells.

Authors:  Yongjie Zhang; Shalenie P den Braver-Sewradj; Michiel W den Braver; Steven Hiemstra; Nico P E Vermeulen; Bob van de Water; Jan N M Commandeur; J C Vos
Journal:  Front Pharmacol       Date:  2018-04-18       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.